Prognostic relevance of MYD88 mutations in CLL: the jury is still out
| Autor: | Richard Rosenquist, Lesley-Ann Sutton, Davide Rossi, Paolo Ghia, Lydia Scarfò, Andreas Agathangelidis, Gianluca Gaidano, Šárka Pospíšilová, Jana Kminkova, Anastasia Hadzidimitriou, Kostas Stamatopoulos, Panagiotis Baliakas |
|---|---|
| Přispěvatelé: | Baliakas, P, Hadzidimitriou, A, Agathangelidis, A, Rossi, D, Sutton, La, Kminkova, J, Scarfo, L, Pospisilova, S, Gaidano, G, Stamatopoulos, K, Ghia, P, Rosenquist, R |
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male Chronic lymphocytic leukemia Immunology Kaplan-Meier Estimate medicine.disease_cause Biochemistry Genome 03 medical and health sciences Exon 0302 clinical medicine hemic and lymphatic diseases Biomarkers Tumor medicine Humans Gene Aged 030304 developmental biology Aged 80 and over Genetics 0303 health sciences Mutation business.industry Cell Biology Hematology Middle Aged Prognosis medicine.disease Leukemia Lymphocytic Chronic B-Cell 3. Good health Leukemia 030220 oncology & carcinogenesis Myeloid Differentiation Factor 88 Female business IGHV@ |
| Zdroj: | Blood |
| ISSN: | 1528-0020 0006-4971 |
| Popis: | Genome surveys have offered a comprehensive view of the genetic landscape of chronic lymphocytic leukemia (CLL), identifying several recurrently mutated genes, including myeloid differentiation primary response 88 (MYD88). The predominant mutation concerns a p.L265P substitution within exon 5,1,2 which leads to constitutive nuclear factor kappaB stimulation, thus conferring a proliferation and survival advantage to the mutant cells.1 MYD88 mutations reach up to 2% to 5% in CLL and are strikingly enriched among patients expressing mutated IGHV genes (M-CLL). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|